4//SEC Filing
Kite Pharma, Inc. 4
Accession 0001209191-16-109313
CIK 0001510580operating
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 9:14 PM ET
Size
17.6 KB
Accession
0001209191-16-109313
Insider Transaction Report
Form 4
Roberts Margo R
Chief Scientific Officer
Transactions
- Sale
Common Stock
2016-03-15$46.34/sh−436$20,204→ 10,910 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2016-03-15−7,500→ 56,250 totalExercise: $0.70Exp: 2023-10-07→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2016-03-15$0.70/sh+7,500$5,250→ 18,155 total - Sale
Common Stock
2016-03-15$45.09/sh−7,815$352,378→ 11,346 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2016-03-15−1,006→ 30,575 totalExercise: $17.00Exp: 2024-06-18→ Common Stock (1,006 underlying) - Exercise/Conversion
Common Stock
2016-03-15$17.00/sh+1,006$17,102→ 19,161 total - Sale
Common Stock
2016-03-15$47.78/sh−255$12,184→ 10,655 total
Footnotes (7)
- [F1]Includes 1,557 shares acquired under the 2014 Employee Stock Purchase Plan on February 19, 2016.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.05 to $46.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.27 to $48.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F6]25% of the 150,000 shares subject to the stock option vested and became exercisable on August 19, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.
- [F7]25% of the 50,000 shares subject to the stock option vested and became exercisable on June 19, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 monthly installments as of the last calendar day of each month following the initial vesting date.
Documents
Issuer
Kite Pharma, Inc.
CIK 0001510580
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001510580
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 9:14 PM ET
- Size
- 17.6 KB